RT Journal Article
T1 Combined effects of smoking and HPV16 in oropharyngeal cancer.
A1 Anantharaman, Devasena
A1 Muller, David C
A1 Lagiou, Pagona
A1 Ahrens, Wolfgang
A1 Holcatova, Ivana
A1 Merletti, Franco
A1 Kjærheim, Kristina
A1 Polesel, Jerry
A1 Simonato, Lorenzo
A1 Canova, Cristina
A1 Castellsague, Xavier
A1 Macfarlane, Tatiana V
A1 Znaor, Ariana
A1 Thomson, Peter
A1 Robinson, Max
A1 Conway, David I
A1 Healy, Claire M
A1 Tjønneland, Anne
A1 Westin, Ulla
A1 Ekström, Johanna
A1 Chang-Claude, Jenny
A1 Kaaks, Rudolf
A1 Overvad, Kim
A1 Drogan, Dagmar
A1 Hallmans, Göran
A1 Laurell, Göran
A1 Bueno-de-Mesquita, H B
A1 Peeters, Petra H
A1 Agudo, Antonio
A1 Larrañaga, Nerea
A1 Travis, Ruth C
A1 Palli, Domenico
A1 Barricarte, Aurelio
A1 Trichopoulou, Antonia
A1 George, Saitakis
A1 Trichopoulos, Dimitrios
A1 Quiros, J Ramon
A1 Grioni, Sara
A1 Sacerdote, Carlotta
A1 Navarro, Carmen
A1 Sánchez, María-José
A1 Tumino, Rosario
A1 Severi, Gianluca
A1 Boutron-Ruault, Marie-Christine
A1 Clavel-Chapelon, Francoise
A1 Panico, Salvatore
A1 Weiderpass, Elisabete
A1 Lund, Eiliv
A1 Gram, Inger T
A1 Riboli, Elio
A1 Pawlita, Michael
A1 Waterboer, Tim
A1 Kreimer, Aimée R
A1 Johansson, Mattias
A1 Brennan, Paul
K1 Human papillomavirus
K1 head and neck cancer risk
K1 interaction
K1 oropharynx cancer
K1 tobacco smoking
AB Although smoking and HPV infection are recognized as important risk factors for oropharyngeal cancer, how their joint exposure impacts on oropharyngeal cancer risk is unclear. Specifically, whether smoking confers any additional risk to HPV-positive oropharyngeal cancer is not understood. Using HPV serology as a marker of HPV-related cancer, we examined the interaction between smoking and HPV16 in 459 oropharyngeal (and 1445 oral cavity and laryngeal) cancer patients and 3024 control participants from two large European multi-centre studies. Odds ratios and credible intervals [CrI], adjusted for potential confounders, were estimated using Bayesian logistic regression. Both smoking [odds ratio (OR [CrI]: 6.82 [4.52, 10.29]) and HPV seropositivity (OR [CrI]: 235.69 [99.95, 555.74]) were independently associated with oropharyngeal cancer. The joint association of smoking and HPV seropositivity was consistent with that expected on the additive scale (synergy index [CrI]: 1.32 [0.51, 3.45]), suggesting they act as independent risk factors for oropharyngeal cancer. Smoking was consistently associated with increase in oropharyngeal cancer risk in models stratified by HPV16 seropositivity. In addition, we report that the prevalence of oropharyngeal cancer increases with smoking for both HPV16-positive and HPV16-negative persons. The impact of smoking on HPV16-positive oropharyngeal cancer highlights the continued need for smoking cessation programmes for primary prevention of head and neck cancer.
PB Oxford University Press
YR 2015
FD 2015-10-05
LK http://hdl.handle.net/10668/10104
UL http://hdl.handle.net/10668/10104
LA en
NO Anantharaman D, Muller DC, Lagiou P, Ahrens W, Holcátová I, Merletti F, et al. Combined effects of smoking and HPV16 in oropharyngeal cancer. Int J Epidemiol. 2016 Jun;45(3):752-61.
NO The ARCAGE study was supported by a grant from the European Commission’s 5th Framework Program (contract QLK1‐2001‐00182). The EPIC study has been supported by the Europe Against Cancer Program of the European Commission (SANCO); Deutsche Krebshilfe, Deutsches Krebsforschungszentrum, German Federal Ministry of Education and Research; Danish Cancer Society; Health Research Fund (FIS) of the Spanish Ministry of Health, Spanish Regional Governments of Andalucia, Asturias, Basque Country, Murcia and Navarra; Catalan Institute of Oncology, Spain; the ISCIII of the Spanish Ministry of Health (RETICC DR06/0020); Cancer Research UK; Medical Research Council, UK; Greek Ministry of Health; Stavros Niarchos Foundation; Hellenic Health Foundation; Italian Association for Research on Cancer (AIRC); Italian National Research Council, Fondazione-IstitutoBanco Napoli, Italy; Associazione Italiana per la Ricerca sul Cancro-AIRC Milan; Compagnia di San Paolo; Dutch Ministry of Public Health, Welfare and Sports; World Cancer Research Fund; Swedish Cancer Society; Swedish Scientific Council; Regional Government of Vasterbotten, Sweden; NordForsk (Centre of excellence programme HELGA), Norway; French League against Cancer (LNCC), France; National Institute for Health and Medical Research (INSERM), France; Mutuelle Generale de l’Education Nationale (MGEN), France; 3M Co, France; Gustave Roussy Institute (IGR), France; and General Councils of France. The serology testing of EPIC prospective study was supported by the National Cancer Institute Intramural Research Program. The work done in this study was supported in part by a grant from the European Commission’s 7th Framework Program (contract FP7-HEALTH-2011–282562) and partly by the Health General Directorate of the French Social Affairs and Health Ministry.
DS RISalud
RD Apr 11, 2025